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Abstract
Background: Prevalence and incidence rates of chronic in-
flammatory demyelinating polyradiculoneuropathy (CIDP) 
are required to determine the impact of CIDP on society. We 
aimed to estimate the prevalence and incidence of CIDP 
worldwide and to determine the effect of diagnostic criteria 
on prevalence and incidence. Method: A systematic review 
was conducted for all published incidence and prevalence 
studies on CIDP until May 18, 2017. Methodological quality 
was assessed using the Methodological Evaluation of Obser-
vational Research checklist. We performed a random effect 
meta-analysis to estimate pooled prevalence and incidence 
rates. Results: Of the 907 studies, 11 were included in the 
systematic review, 5 in the meta-analysis of incidence (818 
cases; 220,513,514 person-years) and 9 in the meta-analysis 
of prevalence (3,160 cases; 160,765,325 population). These 
studies had a moderate quality. The pooled crude incidence 
rate was 0.33 per 100,000 person-years (95% CI 0.21–0.53; 
I2 = 95.7%) and the pooled prevalence rate was 2.81 per 
100,000 (95% CI 1.58–4.39; I2 = 99.1%). Substantial heteroge-
neity in incidence and prevalence across studies seems to be 
partly explained by using different diagnostic criteria. Con-
clusion: These findings provide a starting point to estimate 
the social burden of CIDP and demonstrate the need to 
reach consensus on diagnostic criteria for CIDP.
© 2019 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Chronic inflammatory demyelinating polyradiculo-
neuropathy (CIDP) is a disorder of the peripheral nerves 
and nerve roots causing limb weakness and sensory defi-
cits [1]. CIDP is considered an immune-mediated disor-
der although the pathogenesis and aetiology of CIDP re-
main elusive [2, 3].
The clinical presentation of CIDP is diverse and at least 
15 sets of diagnostic criteria for CIDP have been developed 
to capture the full spectrum of CIDP and its variant forms 
[4–7]. The criteria from the European Federation of Neu-
rological Societies and Peripheral Nerve Society (EFNS/
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PNS) from 2010 are based on a combination of clinical and 
electrodiagnostic characteristics and are currently the 
most widely accepted criteria to confirm the diagnosis of 
CIDP [4]. Proven effective treatments for CIDP are im-
munoglobulins, corticosteroids and plasmapheresis [8]. 
The clinical response to these treatments is usually only 
partial and transient. Most patients with CIDP require 
maintenance treatment for years or even decades [8]. 
CIDP is therefore a disabling disorder with a considerable 
impact on patients and patient-related health care costs 
[9–14]. However, the population-based burden and relat-
ed health costs are unknown. To determine this, we need 
to estimate the incidence and prevalence of CIDP. 
Previous reviews provided an overview of studies that 
investigated the incidence and prevalence of neuromus-
cular disorders, polyneuropathies and rare diseases in 
general [15–17]. However, these reviews were not per-
formed to give an overview of the incidence and preva-
lence of CIDP in specific and no meta-analysis was con-
ducted. Furthermore, the use of different sets of criteria 
to diagnose CIDP may affect the incidence and preva-
lence rates [18]. To better estimate the true frequencies, 
patient numbers of individual studies need to be com-
bined and the incidence and prevalence of CIDP using 
different diagnostic criteria need to be compared.
Our aim was to conduct a systematic review and meta-
analysis to estimate the incidence and prevalence of CIDP 
worldwide and to determine the effect of diagnostic cri-
teria on reported incidence and prevalence rates.
Method
This systematic review was performed according to the Pre-
ferred Reporting Items for Systematic reviews and Meta-Analyses 
guidelines [19]. The protocol of this systematic review was regis-
tered (registration number 2017: CRD42017072270) in PROSPE-
RO (International prospective register of systematic reviews) [20].
Data Sources and Search Strategy
One author (M.C.B.) and a biomedical information specialist 
(Gerdien B. de Jonge) searched in Embase, Medline Epub, Cochrane 
Central, Web of Science and Google Scholar for all published work 
until May 18, 2017 (online suppl. Appendix I; for all online suppl. 
material, see www.karger.com/doi/10.1159/000494291). We used a 
combination of disease-specific terms (CIDP, chronic inflammatory 
demyelinating polyneuropathy) and key words for incidence and 
prevalence (epidemiology, prevalence and incidence). Reference 
lists of obtained articles were reviewed for additional articles.
Study Selection
We included all studies that reported the prevalence and/or in-
cidence of CIDP and met the following criteria: (1) English lan-
guage, (2) population based, (3) cases were identified based on 
fulfilling general accepted diagnostic criteria for CIDP (e.g., 2010 
EFNS/PNS criteria, American Academy of Neurology [AAN] cri-
teria) and (4) original data (i.e., not a review or a duplicate of pre-
viously published data, and full text must have been published). 
There were no limitations regarding the study size and identified 
the number of CIDP cases. We excluded studies that identified 
cases not based on general accepted diagnostic criteria for CIDP 
(e.g., insurance administrative medical codes, patient reports, 
membership patient organization). Studies that reported the prev-
alence and/or incidence in specific disease groups (e.g., diabetic 
population) instead of the general population were excluded. Stud-
ies that reported age and gender-specific prevalence and/or inci-
dence were included.
Eligibility of all articles was determined by one author (M.C.B.) 
and independently checked by another author (C.B.). Titles and 
abstracts of all articles identified by the initial search strategy were 
independently reviewed on relevance. Articles that obviously did 
not meet the inclusion criteria were excluded. The full text of the 
remaining articles was reviewed in detail to assess whether they 
met the inclusion criteria. In case of disagreement, a third author 
(B.C.J.) reviewed the article and consensus was reached through 
discussion.
Data Extraction
Data of included studies was initially extracted by a single au-
thor (M.C.B.) and independently checked by another author 
(C.B.). Discrepancies were resolved by discussion with a third au-
thor (B.C.J.). Extracted information included author, study de-
sign, study period, population (study region, population number, 
person-years, age, CIDP categories), diagnostic criteria used to 
identify CIDP cases, number of identified CIDP patients, gender 
ratio, reported incidence rates (crude, standardized, age- and sex 
adjusted) and reported prevalence rates (crude, standardized, 
age- en sex adjusted). When data needed for the meta-analysis 
(cases, population number and person-years) was missing, we 
asked the corresponding author to provide this additional infor-
mation.
One author (M.C.B.) assessed the methodological quality and 
risk of bias of the included studies. The Methodological Evaluation 
of Observational Research (MORE) checklist [21] was used to ver-
ify methodological quality and risk of bias. This checklist was de-
signed for quality and bias assessment in incidence or prevalence 
studies of chronic diseases, and was previously used in several sys-
tematic reviews [22–28]. Two authors (M.C.B., H.F.L.) modified 
the MORE checklist to provide an applicable checklist for quality 
and bias assessment of the included studies (online suppl. Appen-
dix II). Based on the MORE checklist, general descriptive elements, 
internal validity and external validity items were judged and de-
fined as “OK,” “minor flaw,” “major flaw” or “poor reporting.” We 
used the statistical software IBM SPSS version 21 for descriptive 
analysis of quality and bias assessment.
Statistical Analysis
We performed a random effect meta-analysis to estimate 
pooled incidence and prevalence rates with 95% CI. Heterogeneity 
was assessed using the I2 statistics and visualized using prediction 
intervals. Meta-analysis of the incidence rates was performed us-
ing a Poisson-normal model [29]. To estimate pooled prevalence 
rates we applied the Freeman-Tukey transformation and per-
formed a random effect meta-analysis on the transformed scale 
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[30]. This transformation was necessary, since prevalence rates 
were close to zero. All statistical analyses were performed using R 
version 3.4.1., with the Metafor package version 2.0–0 used to per-
form the meta-analysis [31].
Results
We identified 907 articles in the initial search of which 
295 duplicates were removed. Based on the title and ab-
stract, 554 articles were excluded. After reviewing the full 
text of the remaining articles, 47 articles did not fulfil the 
following inclusion criteria: English language (n = 6), full 
text available (n = 3), reporting prevalence and/or inci-
dence rates (n = 6), fulfilment of general accepted diag-
nostic criteria for CIDP (n = 3), original data (n = 28) and 
no duplication (n = 1). We contacted the corresponding 
authors of 2 studies because of missing data for conduct-
ing a meta-analysis; one author provided the required in-
formation (crude incidence rate, number of cases and 
person-years) [32]; one author could not provide the re-
quired information [33]. Finally, we included 11 publica-
tions for this systematic review of which 9 studies were 
sufficient for meta-analysis of prevalence [9–13, 18, 34–
36] and 5 studies [11, 13, 18, 32, 34] for meta-analysis of 
incidence (Fig. 1). One study determined prevalence and 
incidence twice by using different diagnostic criteria [18]. 
Of this study, only prevalence and incidence rates based 
on the EFNS/PNS 2006 criteria were included in the me-
ta-analysis.
Characteristics of Studies
Most studies were conducted in Europe (n = 7) in-
cluding the United Kingdom (n = 3), Republic of Ireland 
(n = 1), Italy (n = 1), Iceland (n = 1) and Norway (n = 1; 
Table 1). The remaining studies were conducted in Aus-
tralia (n  = 1), Japan (n = 2) and the United States of 
America (n = 1). The population size in the studies varied 
between 135,802 and 127,655,000 patients. Person-years 
varied between 2,857,143 and 127,655,000. Six studies 
used the AAN criteria to define CIDP cases. In 4 studies, 
the EFNS/PNS criteria were used to confirm the diagno-
Records identified through database
searching
(n = 907)
Additional records identified through
other sources
(n = 0)
Records after duplicates removed
(n = 612)
Records screened on title and
abstract
(n = 612)
Records excluded
(n = 554)
Full-text articles excluded, with reasons
(n = 47)
Full-text articles assessed for
eligibility
(n = 58)
Studies included in qualitative
synthesis
(n = 11)
Studies included in quantitative
synthesis (meta-analysis) of incidence
(n = 5)
Studies included in quantitative
synthesis (meta-analysis) of prevalence
(n = 9)
Additional articles after hand searching
reference list of obtained articles
(n = 0)
Id
en
tif
ica
tio
n
Sc
re
en
in
g
El
ig
ib
ili
ty
In
clu
de
d
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart of the study selection process.
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sis of CIDP; 2 studies used the EFNS/PNS 2006 criteria 
and the other 2 studies used the EFNS/PNS 2010 criteria. 
Most studies included all CIDP categories (definite, 
probable and possible CIDP), while 2 studies only in-
cluded definite and probable CIDP. Years for which in-
cidence rates were available varied from 1982 to 2011. 
Years for which the prevalence rates were available var-
ied from 1992 to 2013. 
Methodological Quality of Studies
Methodological quality varied between studies (Table 
2). Measurement of incidence and prevalence rates was 
validated in all studies. We found minor flaws in the 
source of data due to crude incidence and prevalence 
rates and assessment of sampling bias (n = 1). We found 
major flaws in assessment of sampling bias (n = 1) and 
exclusion rate (n = 1). Poor reporting for assessment of 
sampling bias (81.8%), addressment of sampling bias 
(63.6%) and exclusion rate (90.9%) were found in most 
studies. No studies were excluded from the review based 
on insufficient methodological quality.
Incidence
We included 5 incidence studies in the meta-analysis 
of incidence [11, 13, 18, 32, 34]. In the meta-analysis of 
incidence, 818 cases and 220,513,514 person-years were 
included. Crude incidence rates varied between 0.15 and 
0.70 cases per 100,000 person-years (Table 3). The pooled 
crude incidence rate for the total population is 0.33 per 
100,000 person-years (95% CI 0.21–0.53, I2 = 95.7%; pre-
diction interval 0.11–0.98; Fig. 2). If we had included the 
estimated incidence based on the AAN criteria instead of 
based on the EFNS/PNS 2006 criteria of one study [18], 
the pooled incidence rate would have been 0.29 per 
100,000 (95% 0.20–0.43, I2 = 93.3%; prediction interval 
0.12–0.71). The pooled crude incidence rate for studies 
Table 2. Quality and bias assessment of included studies using MORE checklist
OK
n (%)
Minor flaws
n (%)
Major flaws
n (%)
Poor reporting
n (%)
Total
n
General descriptive elements
Aim of study
Incidence
Prevalence
5 (83.3)
9 (90)
0 (0)
0 (0)
0 (0)
0 (0)
1 (16.7)
1 (10)
6
10
Study design 7 (63.6) 0 (0) 0 (0) 4 (36.4) 11
Funding of study 7 (63.6) 0 (0) 0 (0) 4 (36.4) 11
Conflict of interest 4 (36.4) 2 (18.2) 0 (0) 5 (45.5) 11
Ethical approval 5 (45.5) 2 (18.2) 0 (0) 4 (36.4) 11
External validity
Sampling 3 (27.3) 8 (72.7) 0 (0) 0 (0) 11
Assessment of sampling bias 0 (0) 1 (9.1) 1 (9.1) 9 (81.8) 11
Estimate bias
Response rate
Exclusion rate
2 (50)
0 (0)
1 (25)
0 (0)
0 (0)
1 (9.1)
1 (25)
10 (90.9)
4
11
Addressment of sampling bias 4 (36.4) 0 (0) 0 (0) 7 (63.6) 11
Internal Validity
Source of data 4 (36.4) 7 (63.6) 0 (0) 0 (0) 11
Validation 11 (100) 0 (0) 0 (0) 0 (0) 11
Incidence
Type of incidence 
Type of estimation
Reference period
Precision of estimate
6 (100)
3 (50)
6 (100)
4 (66.7)
0 (0)
3 (50)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
2 (33.3)
6
6
6
6
Prevalence
Type of prevalence
Type of estimation
Precision of estimate
1 (10)
3 (30)
5 (50)
9 (90)
7 (70)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
5 (50)
10
10
10
MORE checklist, methodological evaluation of observational research.
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using the AAN criteria is 0.36 per 100,000 person-years 
(95% CI 0.30–0.44, I2 = 0.0%; prediction interval 0.30–
0.44). Data of studies using the EFNS/PNS 2006 and 
EFNS/PNS 2010 criteria was insufficient to conduct a 
crude pooled estimate for these criteria. Overall, the pre-
diction intervals were substantially wider, thereby reflect-
ing the observed heterogeneity between studies. In gen-
eral, the reported crude incidence rates were higher in 
males than females (gender rate ratios varied between 1.5 
and 4.0; Table 3). One study determined age-specific inci-
dence rates [34]. The crude incidence rate in the age group 
of 15 years and older was 0.54 per 100,000 person-years 
(0.40 per 100,000 person-years in age-group of 15–55 
years and 0.73 per 100,000 person-years in the age-group 
older than 55 years) compared to a crude incidence rate of 
0.06 per 100,000 person-years in age-group 0–15 years. 
Author and year Incidence (95% CI)
Hafsteinsdottir, 2016
Rajabally, 2009*
Iijima, 2008
Chiò, 2007
McLeod, 1999
RE model
For all studies (LRT = 139.63, df = 4, p = 0.00, I2 = 95.7%)
Prediction interval
*-EFNS/PNS criteria
0.25 [0.15, 0.41]
0.70 [0.45, 1.09]
0.47 [0.43, 0.51]
0.37 [0.30, 0.45]
0.15 [0.12, 0.19]
0.33 [0.21, 0.53]
[0.11, 0.98]
10.80.60.40.20
Incidence per 100,000 person-years
Fig. 2. Pooled crude incidence rate using the random-effects model. RE model, random-effects model.
Table 3. Incidence rates
Study author, year, and 
reference number
Number 
of cases
Number 
of male
Number 
of female
Gender rate 
ratio cases, 
male/female
Total incidence per 
100,000 population 
(95% CI)* Male incidence per 100,000 population (95% CI)* Female incidence per 100,000 population (95% CI)* Gender rate ratio incidence, male/female
Hafsteinsdottir and 
Olafsson [32], 2016
15# NR NR NR 0.25#
0.3 (0.04–2.47)*** NR NR NR
Rajabally et al. [18], 2009
EFNS/PNS 2006 criteria
AAN criteria
20
10†
13
NR
7
NR
1.9†
NR
0.70 (0.43–1.08)
0.35 (0.17–0.64)
0.92 (0.49–1.58)
0.56 (0.24–1.10)
0.48 (0.19–0.99)
0.14 (0.02–0.50)
1.9†
4.0†
Laughlin et al. [33], 2009 NR NR NR NR 1.4 (0.8–2.0)!, ***
1.6 (0.9–2.2)*** NR NR NR
Iijima et al. [34], 2008 601 354 247 1.4† 0.48 0.58 0.38 1.5†
Chiò et al. [11], 2007 95 NR NR NR 0.36 (0.29–0.44)
0.34 (0.28–0.42)** 0.51 (0.39–0.65) 0.22 (0.15–0.31) 2.3†
McLeod et al. [13], 1999 87 NR NR NR 0.15 NR NR NR
† Calculated; * crude rate, if not specified otherwise; ** standardized rate; *** age- and sex-adjusted rate; ! excluding MGUS; # provided by author of corre-
sponding study.
NR, not reported; AAN, American Academy of Neurology [6]; EFNS/PNS criteria 2006 [49]. 
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Prevalence
We included 9 studies in the meta-analysis of preva-
lence rates [9–13, 18, 34–36]. In total, 3,160 cases and a 
population size of 160,765,325 were included in the meta-
analysis of prevalence. The crude prevalence rate varied 
between 0.67 and 7.7 cases per 100,000 persons (Table 4). 
The pooled crude prevalence rate for the total population 
is 2.81 per 100,000 (95% CI 1.58–4.39, I2 = 99.1%; predic-
tion interval 0.12–8.78; Fig. 3). If we had included the es-
timated prevalence based on the AAN criteria instead of 
based on the EFNS/PNS 2006 criteria of one study [18], 
the pooled prevalence rate would have been 2.52 per 
100,000 (95% 1.41–3.95, I2 = 99.0%; prediction interval 
0.10–7.91). The pooled crude prevalence rate for studies 
using the AAN criteria is 1.59 per 100,000 (95% CI 0.57–
3.11, I2 = 96.7%; prediction interval 0.01–5.52). The 
pooled crude prevalence rate for studies using the EFNS/
PNS 2006 criteria is 3.67 per 100,000 (95% CI 2.01–5.83, 
I2 = 87.2%; prediction interval 1.18–7.52). While we find 
that studies using the EFNS/PNS 2006 criteria obtain 
higher prevalence rates than studies using the AAN crite-
ria, the difference between the 2 estimates is not signifi-
cant (p = 0.11). One study described prevalence using the 
EFNS/PNS 2010 criteria (5.87 per 100,000) [36]. Overall, 
the prediction intervals were substantially wider, thereby 
reflecting the observed heterogeneity between studies. In 
general, reported crude prevalence rates were higher in 
males than in females (gender rate ratios varied between 
1.4 and 4.4; Table 4). Five studies determined age-specif-
ic prevalence rates [9, 11, 13, 18, 34]. Reported age-groups 
varied between studies. Overall, the prevalence increased 
with age (Table 5).
Discussion
Our meta-analysis provides a pooled crude incidence 
rate for CIDP of 0.33 per 100,000 (95% CI 0.21–0.53; pre-
diction interval 0.11–0.98) person-years and a pooled 
crude prevalence rate of 2.81 per 100,000 (95% CI 1.58–
4.39; prediction interval 0.12–8.78) persons. Reported in-
cidence and prevalence of CIDP showed substantial het-
erogeneity across studies. This heterogeneity may partly 
be explained by the use of different diagnostic criteria. 
Most CIDP patients were male and the incidence and 
prevalence of CIDP increased with age. We observed no 
evident geographical variation in the incidence or preva-
lence rates.
Table 4. Prevalence rates
Study author, year and 
reference number
Number 
of cases
Number 
of male
Number 
of female
Gender ratio
cases, male/
female
Total prevalence per 
100,000 population 
(95% CI)* Male prevalence per 100,000 population (95% CI)* Female prevalence per 100,000 population (95% CI)* Gender ratio prevalence, male/female
Lefter et al. [36], 2017 202 NR NR NR 5.87 (5.06–6.68)# NR NR NR
Mahdi-Rogers and Hughes 
[9], 2014
101 66 35 1.9† 2.84 (2.31–3.45)
2.92 (2.39–3.56)** 3.84 (2.97–4.89) 1.90 (1.32–2.65) 2.0†
Rajabally et al. [18], 2009
EFNS/PNS 2006 criteria
AAN criteria
46
19
34
14
12
5
2.8†
2.8† 4.77 (3.49–6.37)1.97 (1.19–3.08) 6.73 (4.60–9.50)2.94 (1.61–4.94) 2.87 (1.57–4.81)1.02 (0.33–2.39) 2.3†2.9†
Laughlin et al. [33], 2009 11 NR NR NR 10.3 (4.2–16.4)*** NR NR NR
Iijima et al. [34], 2008 2,433 1,495 938 1.6† 1.61 2.01 1.23 1.6†
Chiò et al. [11], 2007 155 105 50 2.1† 3.58 (3.02–4.20)
3.41 (2.92–3.98)** 5.02 (4.13–6.10) 2.23 (1.65–2.94) 2.3†
Mygland and Monstad [10], 
2001
12 NR NR NR 7.7 (3.2–12.2) NR NR NR
McLeod et al. [13], 1999 112 64 48 1.3† 1.9 (1.5–2.2) 2.2 (1.7–2.8) 1.6 (1.2–2.1) 1.4†
Lunn et al. [12], 1999 94 NR NR NR 0.67 NR NR NR
Kusumi et al. [35], 1995 5 4 1 4.0† 0.81 1.36 0.31 4.4†
† Calculated; * crude rate; if not specified otherwise; ** standardized rate; *** age- and sex-adjusted rate; # prevalence rates is expressed as case/100,000 adults.
NR, not reported; AAN criteria, American Academy of Neurology criteria [6]; EFNS/PNS 2006 criteria [49]. 
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Interestingly, males are also overrepresented in other 
immune-mediated neuropathies including the Guillain-
Barré syndrome (GBS) and multifocal motor neuropathy 
[9, 37–40]. The male predominance in these immune-
mediated neuropathies is unexplained and deviates from 
female predominance in many classic autoimmune dis-
orders [41–43]. A male predominance has also been sug-
gested for other forms of polyneuropathies, suggesting 
that males are more at risk to develop a polyneuropathy 
[44, 45]. However, a recent comprehensive overview of 
the literature indicated that polyneuropathies in general 
are more common in females [15]. Older people seem to 
be more at risk to develop CIDP. An increasing incidence 
with age has also been demonstrated for GBS and poly-
neuropathies in general [39, 44]. 
The pooled incidence and prevalence rates should be 
read cautiously because of the substantial heterogeneity 
between the included studies. A critical determinant in 
these studies is the used case definition, since more than 
15 different sets of diagnostic criteria for CIDP have been 
proposed in literature. Our meta-analysis suggests that 
studies using the AAN criteria found lower incidence and 
prevalence rates than studies using the EFNS/PNS 2006 
criteria, and lower prevalence rates than studies using the 
EFNS/PNS 2010 criteria. One study determined preva-
lence and incidence rates for the AAN en EFNS/PNS 2006 
criteria in the same population and found significantly 
(McNemar’s exact test; p < 0.0001) higher rates when us-
ing the EFNS/PNS 2006 criteria for prevalence (1.97 vs. 
4.77 per 100,000) and incidence (0.35 vs. 0.70 per 100,000) 
[18]. These differences are likely related to the variation 
in sensitivity and specificity of these diagnostic criteria. 
The AAN criteria are considered most specific but are less 
sensitive presumably due to requirement of electrophysi-
ological evidence of a minimum of 5 or 6 demyelinating 
findings in 2 nerves, and of abnormalities in cerebrospi-
nal fluid and/or nerve biopsy studies for a diagnosis of 
definite CIDP [6, 46–48]. Overall, EFNS/PNS criteria 
have a higher sensitivity, likely because in contrast to the 
AAN criteria, only 1 or 2 demyelinating findings are re-
quired to diagnose CIDP, with or without additional test-
ing, but are still highly specific presumably due to the 
higher thresholds for demyelinating features [6, 46–49]. 
The higher specificity and lower sensitivity of de AAN 
criteria seem to explain the reason behind the lower inci-
dence and prevalence rates when using the AAN criteria. 
However, in our study, the difference between the pooled 
estimate using the AAN criteria and the pooled estimate 
using the EFNS/PNS 2006 criteria for prevalence was not 
significant, presumably due to the low number of preva-
lence studies using these criteria. The number of inci-
dence studies using the AAN, EFNS/PNS 2006 and EFNS/
Author and Year Prevalence (95% CI)
Lefter, 2017
Mahdi-Rogers, 2014
Rajabally, 2009*
Iijima, 2008
Chiò, 2007
Mygland, 2001
McLeod, 1999
Lunn, 1999
Kusumi, 1995
RE model
For all studies (Q = 429.79, df = 8, p = 0.00, I2 = 99.1%)
Prediction interval
*-EFNS/PNS criteria
5.87 [5.09, 6.71]
2.84 [2.31, 3.42]
4.77 [3.49, 6.26]
1.91 [1.83, 1.98]
3.58 [3.03, 4.16]
7.72 [3.88, 12.79]
1.87 [1.54, 2.23]
0.67 [0.54, 0.81]
0.81 [0.23, 1.72]
2.81 [1.58, 4.39]
[0.12, 8.78]
10.007.505.002.500
Prevalence per 100,000
Fig. 3. Pooled crude prevalence rate using the random-effects model. RE model, random-effects model.
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PNS 2010 criteria was insufficient to determine signifi-
cance between studies using different criteria. Only one 
incidence study used the most recent EFNS/PNS criteria 
(2010) to confirm the diagnosis of CIDP. In contrast, this 
study found a lower incidence rate compared to studies 
using the AAN criteria, which may be explained by the 
exclusion of the category of patients with a “possible” 
CIDP in this study [32]. Of one study, we included esti-
mates based on the EFNS/PNS 2006 criteria and excluded 
estimates based on the AAN criteria in the meta-analysis 
to avoid overrepresentation of this study in our sample 
[18]. We found no large differences in the pooled preva-
lence and incidence between only including estimates 
based on the AAN criteria or only including estimates 
based on the EFNS/PNS 2006 criteria of this study. The 
reported incidence and prevalence rates are also influ-
enced by differences in inclusion and exclusion criteria 
between the studies. Particularly relevant is whether pa-
tients are included with additional diabetes mellitus or 
monoclonal gammopathy of undetermined significance. 
In addition, not all studies included the full range of ages 
of patient with CIDP. One study excluding patients 
younger than 18 years observed a relatively highly preva-
lence rate (5.87 per 100,000 adults; 95% CI 5.06–6.68), 
that is probably explained by the increase of CIDP with 
age [36]. In conclusion, the use of different diagnostic cri-
teria seems to affect the observed incidence and preva-
lence rates of CIDP but also differences in the use of oth-
er inclusion criteria seem to play a role. However, this 
should be read cautiously because significance between 
diagnostic criteria could not be demonstrated.
The prevalence of a disease depends on the disease du-
ration. In clinical practice, it may be difficult to discrimi-
nate between patients with active disease and patients 
with residual nerve damage but inactive disease. The 
CIDP Disease Activity Status tool has been developed to 
define long-term outcomes in CIDP and to classify pa-
tients as cured if they have a stable neurological examina-
tion (either normal or abnormal) and are off all treatment 
for 5 or more years [50]. However, the concept of being 
cured in CIDP is questionable, because patients may re-
lapse even years after the disease became inactive [50, 51]. 
Most studies in our meta-analysis did not define the dis-
ease activity status or whether “cured” patients were ex-
cluded and this could have influenced the reported prev-
alence of CIDP. Long-term follow-up studies recording 
the disease activity status are needed to more accurately 
estimate the prevalence.
The observed incidence and prevalence rates may 
seem to increase in more recent studies, but no statistical Ta
b
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Conclusion
Our meta-analysis provides an estimate of the preva-
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tify risk factors for developing CIDP, such as infections 
and vaccinations preceding the onset of CIDP symp-
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CIDP using the revised EFNS/PNS criteria. 
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